Logo: to the web site of Uppsala University

uu.sePublications from Uppsala University
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Discovery of the 4-aminopiperidine-based compound EM127 for the site-specific covalent inhibition of SMYD3
Photoreact Natl Res Council, Inst Organ Synth, I-40129 Bologna, Italy..
Alma Mater Studiorum Univ Bologna, Dept Pharm & Biotechnol, Bologna, Italy.;Univ Bologna, Ctr Appl Biomed Res, Bologna, Italy..
Photoreact Natl Res Council, Inst Organ Synth, I-40129 Bologna, Italy..
Alma Mater Studiorum Univ Bologna, Dept Pharm & Biotechnol, Bologna, Italy..
Show others and affiliations
2022 (English)In: European Journal of Medicinal Chemistry, ISSN 0223-5234, E-ISSN 1768-3254, Vol. 243, article id 114683Article in journal (Refereed) Published
Abstract [en]

Recent findings support the hypothesis that inhibition of SMYD3 methyltransferase may be a therapeutic avenue for some of the deadliest cancer types. Herein, active site-selective covalent SMYD3 inhibitors were designed by introducing an appropriate reactive cysteine trap into reversible first-generation SMYD3 inhibitors. The 4-amino-piperidine derivative EM127 (11C) bearing a 2-chloroethanoyl group as reactive warhead showed selectivity for Cys186, located in the substrate/histone binding pocket. Selectivity towards Cys186 was retained even at high inhibitor/enzyme ratio, as shown by mass spectrometry. The mode of interaction with the SMYD3 substrate/ histone binding pocket was revealed by crystallographic studies. In enzymatic assays, 11C showed a stronger SMYD3 inhibitory effect compared to the reference inhibitor EPZ031686. Remarkably, 11C attenuated the proliferation of MDA-MB-231 breast cancer cell line at the same low micromolar range of concentrations that reduced SMYD3 mediated ERK signaling in HCT116 colorectal cancer and MDA-MB-231 breast cancer cells. Furthermore, 11C (5 mu M) strongly decreased the steady-state mRNA levels of genes important for tumor biology such as cyclin dependent kinase 2, c-MET, N-cadherin and fibronectin 1, all known to be regulated, at least in part, by SMYD3. Thus, 11C is as a first example of second generation SMYD3 inhibitors; this agent represents a covalent and a site specific SMYD3 binder capable of potent and prolonged attenuation of methyltransferase activity.

Place, publisher, year, edition, pages
Elsevier, 2022. Vol. 243, article id 114683
Keywords [en]
Covalent inhibitor, SMYD3, Lysine methyltransferase, Epigenetic inhibitors, Cancer target therapy
National Category
Biochemistry Molecular Biology
Identifiers
URN: urn:nbn:se:uu:diva-487227DOI: 10.1016/j.ejmech.2022.114683ISI: 000862667200009PubMedID: 36116234OAI: oai:DiVA.org:uu-487227DiVA, id: diva2:1710530
Funder
EU, Horizon 2020Available from: 2022-11-14 Created: 2022-11-14 Last updated: 2025-02-20Bibliographically approved
In thesis
1. Structural studies of drug targets and a drug metabolizing enzyme
Open this publication in new window or tab >>Structural studies of drug targets and a drug metabolizing enzyme
2023 (English)Doctoral thesis, comprehensive summary (Other academic)
Abstract [en]

The work presented in this thesis describes how structural information about a protein can be acquired, and how it can be used to answer scientific questions about proteins’ function, their dynamic behaviour and their interactions with other proteins or ligands.

The catalytic function of the pyrimidine-degrading, drug metabolizing enzyme β-ureidopropionase (βUP) is dependent on the shift between oligomeric states. Substitution of amino acids H173 and H307 in the dimer-dimer interface and E207Q in the active site revealed that these are crucial for βUP activation. Inhibition studies of substrate-and product analogues allowed for a hypothesis that the ability to interact with F205 might distinguish activators from inhibitors. The first structure of the activated higher oligomer state of human βUP was determined using cryogenic electron microscopy, and confirmed that the closed entrance loop conformations and dimer-dimer interfaces are conserved between HsβUP and DmβUP. 

Interactions between the epigenetic drug target SET and MYND domain containing protein 3 (SMYD3) and possible inhibitors were investigated. A crystal structure confirmed the covalent bond of a rationally designed, targeted inhibitor to C186 in the active site of SMYD3. A new allosteric binding site was discovered using a biosensor screen with a blocked active site. Crystal structures revealed the location of the new binding site, and the binding mode of the (S)-and (R) enantiomers of the allosteric inhibitor. Lastly, a fragment based drug discovery approach was taken, co-crystallizing and soaking SMYD3 with hits from a fragment screen. This resulted in four crystal structures with weak electron density of fragments at several locations in the enzyme. 

The dynamic acetylcholine binding protein (AChBP) is a homologue of a Cys-loop type ligand gated ion channel. Hits from various biosensor screens, of which some indicated conformational changes, were co-crystallized with AChBP. Seven crystal structures of AChBP in complex with hit compounds from the biophysical screens were determined. Small conformational changes in the Cys-loop were detected in several of the crystal structures, coinciding with the results from the biosensor screens.

In these studies, we explore new strategies for the investigation of the function and regulation of proteins relevant in drug discovery and optimization.

Place, publisher, year, edition, pages
Uppsala: Acta Universitatis Upsaliensis, 2023. p. 65
Series
Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Science and Technology, ISSN 1651-6214 ; 2292
Keywords
Biochemistry, Biophysics, Protein structure, X-ray crystallography, Cryogenic electron microscopy, Enzymology, Drug discovery, Pyrimidine degradation
National Category
Biophysics Biochemistry Molecular Biology
Research subject
Biochemistry
Identifiers
urn:nbn:se:uu:diva-508764 (URN)978-91-513-1865-3 (ISBN)
Public defence
2023-09-26, B41, BMC, Husargatan 3, Uppsala, 09:00 (English)
Opponent
Supervisors
Available from: 2023-09-04 Created: 2023-08-08 Last updated: 2025-02-20

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMed

Authority records

Cederfelt, DanielaTalibov, Vladimir ODanielson, U. Helena

Search in DiVA

By author/editor
Cederfelt, DanielaTalibov, Vladimir ODanielson, U. Helena
By organisation
BiochemistryScience for Life Laboratory, SciLifeLab
In the same journal
European Journal of Medicinal Chemistry
BiochemistryMolecular Biology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 300 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf